OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Clinical trials for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) explained in plain language.
Never miss a new study
Get alerted when new OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) trials appear
Sign up with your email to follow new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Heart drug mavacamten under Real-World watch in japan
Disease control Recruiting nowThis study monitors 200 people in Japan who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Researchers will track side effects and how well the drug works in everyday medical practice. The …
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Could a common supplement ease a rare heart condition?
Disease control Recruiting nowThis study tests a medicine called ademetionine in people with a heart condition that makes the heart muscle too thick, blocking blood flow. The goal is to see if it helps patients exercise better and feel less tired. About 44 adults will take either the medicine or a placebo for…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Phase: PHASE2 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Heart drug mavacamten under the microscope in Real-World patient study
Knowledge-focused Recruiting nowThis study is tracking 362 adults with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow) who are taking the drug mavacamten in regular U.S. clinics. Researchers want to see how the drug affects blood pressure, heart functi…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 17, 2026 11:36 UTC